Curcumin ameliorates health-related quality of life in patients with liver cirrhosis: A randomized, double-blind placebo-controlled trial. (March 2020)

• Record Type: Journal Article
• Authors: Nouri-Vaskeh, Masoud; Afshan, Hossein; Malek Mahdavi, Aida; Alizadeh, Leila; Fan, Xiude; Zarei, Mohammad
• Is Part Of: Complementary therapies in medicine. Volume 49(2020)
• Publication Date: 2020-03
• Subjects: Curcumin -- Curcuma -- Quality of life -- End stage liver disease -- Liver cirrhosis; Alternative medicine -- Periodicals; Complementary Therapies -- Periodicals; Médecines parallèles -- Périodiques; Thérapeutique -- Périodiques; Alternative medicine; Electronic journals; Periodicals; 615.5
• DOI: 10.1016/j.ctim.2020.102351
• Languages: English
• ISSNs: 0965-2299

Abstract

Highlights: Curcumin increased overall scores as well as most of CLDQ domains, the Physical and Mental health (Total) scores and most of SF-36 domains considerably. Curcumin reduced most of LDSI 2.0 domains significantly. Significant differences were noticed between curcumin and placebo groups in CLDQ domains and overall scores, LDSI 2.0 domains and overall scores, SF-36 Physical and Mental health (total) scores and all its domains scores. Abstract: Objectives: Current study aimed to find the effects of curcumin on quality of life (QoL) in liver cirrhotic patients. Design: In this randomized double-masked placebo-controlled trial, 70 cases with liver cirrhosis aged 20–70 years were randomly divided into two groups to receive 1000 mg/day curcumin (n = 35) or placebo (n = 35) for 12 weeks. The health-related QoL (HRQoL) was assessed by CLDQ, LDSI 2.0, and SF-36. Results: Fifty-eight patients (28 in curcumin and 30 in placebo groups) finished the research. Compared with baseline, overall scores as well as most of CLDQ domains (e.g. Fatigue, Emotional Function, Worry, Abdominal Symptoms, and Systemic Symptoms) and the Physical and Mental health (Total) scores and most of SF-36 domains (e.g. Physical Functioning, Bodily Pain, Vitality, Social Functioning, and Mental Health) increased considerably ( P < 0.05) after curcumin administration. Furthermore, curcumin reduced most of LDSI 2.0 domains (e.g. Itch, Joint pain, Pain in the right upper abdomen, Sleeping during the day, Decreased appetite, Depression, Fear of complication, Jaundice, Hindrance in Financial Affairs, Change in use of time, Decreased sexual interest, and Decreased sexual activity) significantly ( P < 0.05). Significant differences were noticed between two groups in CLDQ domains and overall scores, LDSI 2.0 domains and overall scores, SF-36 Physical and Mental health (total) scores and all its domains scores (P < 0.05), adjusting for baseline values and disease duration. Conclusions: Curcumin improved QoL in liver cirrhotic patients according to CLDQ, LDSI 2.0, and SF-36 domains. Additional studies are warranted to consider curcumin as a safe, accessible, and low-cost complementary therapeutic option in cirrhosis.